APL A.I CyberSecurity Scoring
03/04/2026
Access Monitoring Plan
Access Monitoring Plan
No incidents recorded for AUROBINDO PHARMA LTD in 2026.
No incidents recorded for AUROBINDO PHARMA LTD in 2026.
No incidents recorded for AUROBINDO PHARMA LTD in 2026.
Pharmaceutical Manufacturing
Championing the missions that matter™. Catalent, Inc. is a leading global contract development and manufacturing organization (CDMO) and trusted partner to pharma, biotech, and consumer health companies worldwide. We put patients first in everything we do, helping people live better and healthier lives through every product we help develop, manufacture and deliver. With over 1,000 active development programs at any given time, we launch over 100 new products and line extensions annually. Catalent has supported half of all FDA approvals over the past decade, and our teams working at over 40 global sites help us produce over 60 billion doses every year. Our strength lies in our people: teams across our more than 40 sites and thousands of passionate scientists and technicians who bring expertise in development sciences, delivery technologies, and multi-modality manufacturing. What unites us is our commitment to championing our partners’ missions as our own, anticipating customer needs, solving complex challenges and ultimately making a difference in the lives of patients across the globe. At Catalent, you will be able to directly have an impact, solving problems and ensuring excellence for our customers. Our focus on delivering meaningful outcomes alongside our customers means your work directly impacts millions of people around the world. Join us in championing the missions that matter. Catalent is headquartered in Tampa, Florida, with over 40 global sites. Visit www.catalent.com to learn more.
Lupin Limited is a global pharmaceutical leader headquartered in Mumbai, India, with products distributed in over 100 markets. Lupin specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. Trusted by healthcare professionals and consumers globally, the company enjoys a strong position in India and the U.S. across multiple therapy areas, including respiratory, cardiovascular, anti-diabetic, anti-infective, gastrointestinal, central nervous system, and women’s health. Lupin has 15 state-of-the-art manufacturing sites and 7 research centers globally, along with a dedicated workforce of over 23,000 professionals. Lupin is committed to improving patient health outcomes through its subsidiaries – Lupin Diagnostics, Lupin Digital Health, and Lupin Manufacturing Solutions.
Established in 1984, we are a global pharmaceutical company headquartered in Hyderabad, India. Driven by our purpose of ‘Good Health Can’t Wait’, we work to provide access to affordable and innovative medicines. We offer a portfolio of products and services including APIs, generics, branded generics, biosimilars and OTC. Our major markets include USA, India, Russia & CIS countries, China, Brazil and Europe. As a company with a history of deep science that has led to several industry firsts, we continue to plan ahead and invest in future growth drivers such as access to novel molecules, digital therapeutics and consumer healthcare. As an early adopter of sustainability and ESG actions, we released our first Sustainability Report in 2004. Our current ESG goals aim to set the bar high in environmental stewardship; access and affordability for patients; diversity; and governance. For more information, log on to: www.drreddys.com. Caution Notice: Dr. Reddy's has been made aware of candidates receiving fraudulent job opportunities from unauthorised recruiting agencies or people impersonating Dr. Reddy's leaders. These fraudulent jobs may be advertised on employment sites or mimic our careers site and company email addresses. Please know that Dr. Reddy's Laboratories has no affiliation or connection to these situations. Dr. Reddy's (and its associated/group companies) follows a formal recruitment process through its own HR department. Please report immediately in case you suspect a fraudulent job. You may raise your concern by: Accessing https://drreddys.ethicspoint.com. Calling on the hotline number. List of hotline numbers are available in https://drreddys.ethicspoint.com. The hotline is available 24x7 in multiple languages. Writing to [email protected] or [email protected]. For our community guidelines on LinkedIn, please visit: https://shorturl.at/LTvNZ
Torrent Pharma, with annual revenues of more than Rs 10,700 crores, is the flagship Company of the Torrent Group, with group revenues of Rs 41,000 crores. It is ranked 5th in the Indian Pharma Market and is among the Top 5 in the therapeutic segments of Cardiovascular (CV), Central Nervous System (CNS), Gastro-intestinal (GI), Vitamins Minerals Nutritionals (VMN) and Cosmo-Dermatology. The Company also has significant presence in diabetology, pain management, gynaecology, oncology and anti-infective segments. Torrent has 8 manufacturing facilities , of which 5 are USFDA approved. With R&D as the backbone for its growth in domestic & overseas market, it has invested significantly in R&D capabilities with state-of-the-art R&D infrastructure employing around 800 scientists. The acquisition of Elder Pharma's Indian branded business in 2013, Dermaceuticals business of Zyg Pharma in 2015, API plant of Glochem Industries in 2016, Women healthcare brands from Novartis and Unichem's Indian branded business along with its Sikkim Plant in 2017 strengthened Torrent Pharma's position in the Indian Pharma market. Torrent Pharma started international acquisitions in 2005 with entry into the German market. Today, the Company has presence in more than 50 countries and is ranked No. 1 among the Indian pharma Companies in Brazil and Germany. Torrent Pharma is committed towards “not just healthcare but lifecare.”
Fundada há mais de 60 anos e com capital 100% nacional, a EMS é a líder do mercado farmacêutico brasileiro há 19 anos consecutivos, pertencente ao Grupo NC, um dos maiores conglomerados brasileiros. A empresa ocupa também a liderança no segmento de genéricos desde 2013 (IQVIA 2019) e está entre os maiores laboratórios em preferência prescritiva no Brasil. Tem forte presença em PDVs de todo o país e atuação nas áreas de Prescrição Médica, Genéricos, Marcas, OTC e Hospitalar, fabricando medicamentos para praticamente todas as especialidades da Medicina. Possui fábricas em Hortolândia (SP), Manaus (AM), Brasília (DF) e Jaguariúna (SP). A EMS apoia ações de responsabilidade social dentro e fora do Brasil. Em 2017, por exemplo, o laboratório fechou parceria com a Organização Mundial da Saúde (OMS) para doar 100% do medicamento para erradicar, nos próximos anos, em todo o planeta, a bouba, doença negligenciada. A EMS é a única farmacêutica no mundo a ter abraçado essa causa. O Centro de Pesquisa & Desenvolvimento da EMS no Brasil é o mais moderno da América Latina. Na Itália, a EMS tem o laboratório de pesquisas MonteResearch. O foco de atuação do laboratório é a inovação nas seguintes frentes: inovação incremental; genéricos de alta complexidade; medicamentos biotecnológicos, por meio da empresa Bionovis; e inovação disruptiva, por meio da Brace Pharma, empresa da EMS instalada em 2013 nos Estados Unidos. Ainda, nos EUA, por meio de sua controlada Vero Biotech, localizada em Atlanta, Geórgia, a EMS, recentemente, obteve a aprovação de seu primeiro produto revolucionário submetido à FDA (Food and Drug Administration), posicionando o laboratório como uma empresa de inovação no mercado global. Com aportes frequentes em infraestrutura fabril e em pesquisa de ponta para desenvolver produtos inovadores, eficazes e seguros, a EMS, que já exporta para mais de 40 países, está preparada para continuar cuidando das pessoas que querem viver cada vez mais e melhor.
A consumer-led global pharmaceutical company, creating healthy doses of life since 1949. When you operate in an industry like pharmaceuticals, your work goes way beyond creating ‘products for customers’. It is different from any other domain – there lies a higher sense of responsibiliti and a need for utmost integriti in everything you do. As you serve millions of lives, high qualiti standards become a pre-requisite, and safeti of your people and consumers always comes first. All this, while ensuring that each life you touch is treated with respect and digniti. For more than 60 years, Ipca has been a crucial healthcare partner in over 120 countries across the 6 continents. We are a fully-integrated pharmaceutical company that manufactures over 350 formulations and 80 APIs for various therapeutic segments. Today, we are one of the world’s largest manufacturers and suppliers of over a dozen APIs. These are produced from scratch at fully-automated manufacturing facilities, approved by the world’s most discerning drug regulatory authorities like UK-MHRA, EDQM-Europe, and WHO-Geneva, among others. - One of the largest suppliers of these APIs worldwide with manufacturing leadership in over 12 APIs globally - 15 APIs & 11 Formulations manufacturing facility across the globe Leader in DMARDs (Disease Modifying Anti-Rheumatic Drugs) treatment for Rheumatoid Arthritis - Leading brands in Pain, Rheumatology, Antimalarials and Hair care therapy - 4 formulations rank amongst the top 300 brands of IPM as per IQVIA
Novartis is an innovative medicines company. Every day, working to reimagine medicine to improve and extend people’s lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach more than 250 million people worldwide. Find out more at https://www.novartis.com See our community guidelines: https://go.novartis.social/3Nboxki
Lonza is a pioneer and world leader in the CDMO industry, setting the pace with cutting-edge science, smart technology, and lean manufacturing. United by a common purpose, we turn our customers’ breakthrough innovations into viable therapies and manufacture the medicines of tomorrow. Founded in Switzerland in 1897, our company is the first and original CDMO, and today we are more dynamic, agile and forward-focused than ever before. As one of the largest Western CDMOs, we bring together a global team of around 18,500 colleagues across five continents to deliver comprehensive, integrated solutions for our customers' complex needs. For our customers and their patients, we bring quality, safety and reliability to bring life-enhancing and life-saving treatments to market at speed and at scale. For our colleagues, we strive to create a sense of belonging and inclusion where every person can thrive and bring their best.
The Zydus Group with an overarching purpose of empowering people with freedom to live healthier and more fulfilled lives, is an innovative, global life-sciences company that discovers, develops, manufactures, and markets a broad range of healthcare therapies. The group employs over 27000 people worldwide and is driven by its mission to unlock new possibilities in life-sciences through quality healthcare solutions that impact lives. The group aspires to transform lives through pathbreaking discoveries.
Latest updates, reports, and threat intel affecting the global network.
Over the course of his career, Gyan Pandey has held senior leadership roles at Voltas Limited, Aurobindo Pharma Limited and Oracle...
Polycab India Limited has announced the appointment of Mr. Gyan Pandey as Executive President and Chief Digital & Information Officer...
Polycab India Limited has appointed Mr. Gyan Pandey as Executive President and Chief Digital & Information Officer effective February 16,...
Polycab India Limited has officially announced the appointment of Mr. Gyan Pandey to a key leadership role within its senior management team...
At the XIV Convocation, 59 of the 71 gold medals were awarded to women. Women also formed 68 per cent of the 26501 students who graduated...
HYDERABAD: Pharma major Aurobindo Pharma is acquiring the non-oncology prescription business of Mumbai-based Khandelwal Laboratories Pvt Ltd...
This strategic partnership aims to combine the company's domain expertise in defence-grade electronic systems with Sibersentinel...
Accenture said on Thursday it will buy Australian cybersecurity firm CyberCX in its largest-ever deal in the sector.
Stock brokers are classified as Qualified REs if they have more than 10 lakh clients or over ₹10 lakh crore in turnover.
h2o is an HTTP server with support for HTTP/1.x, HTTP/2 and HTTP/3. Prior to commit 6b5370d, h2o is vulnerable to a Denial of Service attack when calling alloca under certain conditions. When serving static files, h2o builds the file path on stack, by calling alloca. The maximum size of the memory allocated using alloca can be as huge as ~600KB, which exceeds the default pthread stack size used by musl libc (128KB). If the amount of memory allocated by alloca exceeds the stack size, the h2o server crashes with a segmentation fault, while it tries to touch the guard page. This issue has been fixed by commit 6b5370d.
h2o is an HTTP server with support for HTTP/1.x, HTTP/2 and HTTP/3. Prior to commit 8dc37cb, when h2o receives a ClientHello message over TLS or QUIC and it contains a zero-length SNI extension, the h2o server runs over the zero-length hostname while trying to copy the hostname, assuming that it is NULL-terminated. This is a potential denial-of-service attack vector in sense that it might trigger segmentation violation. This issue has been fixed by commit 8dc37cb.
Quicly is an IETF QUIC protocol implementation intended primarily for use within the H2O HTTP server. Prior to commit 8b178e6, Quicly is vulnerable to a Denial of Service attack through connection state corruption. In QUIC Invariants, the maximum length of a Connection ID is 255 bytes, while QUIC version 1 further restricts the maximum to 20 bytes. Quicly implements QUIC version 1 and therefore its CID buffers are limited to 20 bytes. However, to be able to respond to unknown versions of QUIC, its packet decoder accepts Connection IDs of up to 255 bytes. As its CID buffers are merely 20 bytes long, Quicly must reject QUIC version 1 packets with Connection IDs longer than that. The command line tool bundled with Quicly has had that check, however the library itself lacked such enforcement. As a consequence, when used by applications that lack their own enforcement, the connection state becoming inconsistent to buffer overrun. Fortunately, the overflow stops within the allocated chunk of memory, but nevertheless, the bug leads to assertion failures. This issue has been fixed by commit 8b178e6.
Quicly is an IETF QUIC protocol implementation intended primarily for use within the H2O HTTP server. Prior to commit 937d0e9, an assertion failure is raised when the total number of valid handshake messages received over a CRYPTO stream of a single packet number space exceeds 32KB, causing a Denial of Service. This issue has been fixed by commit 937d0e9.
Quicly is an IETF QUIC protocol implementation intended primarily for use within the H2O HTTP server. Prior to commit dccf5d4, Quicly was vulnerable to stateless reset injection through lack of packet entry validation. The QUIC protocol is designed to withstand packet injection attacks, once the handshake is complete. Only packets that carry some secret patterns are considered as stateless resets. Quicly allows the peer to share up to 4 such patterns per connection. However, until now, it failed to determine which of the 4 slots that it uses to retain the secret patterns contains a valid entry. As the slots are zero-initialized, the failure meant that, unless the peer advertised 4 of such patterns, an all-zero pattern was treated as a stateless reset.In effect, this allowed an on-path attacker to reset QUIC connections governed by Quicly. This issue has been fixed by commit dccf5d4.
curl -i -X GET 'https://api.rankiteo.com/underwriter-getcompany-history?
linkedin_id=axa' -H 'apikey: YOUR_API_KEY_HERE'
Every week, Rankiteo analyzes billions of signals to give organizations a sharper, faster view of emerging risks. With deeper, more actionable intelligence at their fingertips, security teams can outpace threat actors, respond instantly to Zero-Day attacks, and dramatically shrink their risk exposure window.
Rankiteo is a unified scoring and risk platform that analyzes billions of signals weekly to help organizations gain faster, more actionable insights into emerging threats. Empowering teams to outpace adversaries and reduce exposure.